{"id":3650,"date":"2026-10-07T09:00:00","date_gmt":"2026-10-07T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3650"},"modified":"2026-10-07T19:34:43","modified_gmt":"2026-10-07T23:34:43","slug":"solengepras-meets-phase-iii-parkinsons-endpoint","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3650","title":{"rendered":"Solengepras Meets Phase III Parkinson\u2019s Endpoint"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Cerevance<\/p>\n

Event Type<\/strong><\/p>\n

Phase 3 topline result (primary endpoint met)<\/p>\n

Modality<\/strong><\/p>\n

Small molecule (oral GPR6 inverse agonist)<\/p>\n

Asset<\/strong><\/p>\n

Solengepras<\/p>\n

Target<\/strong><\/p>\n

GPR6<\/p>\n

Disease Area<\/strong><\/p>\n

Parkinson’s disease (motor fluctuations)<\/p>\n

Summary<\/h4>\n

Cerevance reported that once-daily solengepras met the 12-week primary endpoint in Phase III ARISE, reducing daily OFF time versus placebo in levodopa-treated Parkinson\u2019s disease. The result validates the trial\u2019s non-dopaminergic GPR6 strategy at the reported endpoint, but the absolute effect was modest and durability, multiplicity control and a complete dataset remain necessary for clinical interpretation.<\/p>\n

ARISE randomized 341 adults with at least three hours of daily OFF time to 75 mg, 150 mg or placebo for 12 weeks. At 150 mg, mean OFF time changed by -1.56 hours from baseline versus -0.95 with placebo: placebo-adjusted -0.61 hours, p=0.0350. ON time without troublesome dyskinesia increased by 0.60 hours versus placebo, p=0.0468.<\/p>\n

Reported secondary changes included MDS-UPDRS Part II improvement of 1.91 points, p=0.0008, and nominally significant sleepiness and quality-of-life measures. Adverse-event discontinuations were 3.5% in each arm. Dyskinesia occurred in 4.4% at 150 mg versus 1.8% with placebo; several common adverse events were numerically higher at 150 mg.<\/p>\n

Deep Analysis<\/h4>\n

A positive randomized Phase III trial is decision-relevant because GPR6 inverse agonism may modulate indirect-pathway basal-ganglia signaling without directly stimulating dopamine receptors. The -0.61-hour placebo-adjusted OFF-time result is statistically positive but clinically should be considered with patient-reported function, responder distributions, dose response and longer exposure. The short release does not disclose the full hierarchical testing plan or all confidence intervals.<\/p>\n

Interpretation A is genuine non-dopaminergic symptomatic benefit with manageable short-term tolerability. Convergent OFF-time, ON-time and daily-living results support it. Interpretation B is a statistically fragile or clinically modest effect magnified by a short study and selective top-line reporting. The small absolute difference, borderline p values for time measures, absent full multiplicity description and 12-week duration support caution.<\/p>\n

Competitive displacement would depend on reproducibility, safety, convenience and benefit relative to optimized dopaminergic adjuncts, not merely placebo. A second adequate trial, detailed responder and subgroup analyses, longer-term safety, exposure-response and regulator assessment would strengthen the case. Failure to reproduce the OFF-time effect or a material neuropsychiatric, sleep or dyskinesia burden would weaken it.<\/p>\n

Company and Product Background<\/h4>\n

Parkinson\u2019s disease produces motor fluctuations as dopaminergic neurons are lost and levodopa response becomes less stable. OFF time is the daily period when medication benefit wanes. Solengepras is an oral inverse agonist of GPR6, a receptor enriched in striatal indirect-pathway neurons. The program seeks symptomatic improvement through circuit modulation rather than direct dopamine-receptor agonism.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Phase III primary endpoint met at 150 mg: placebo-adjusted OFF time -0.61 hours, p=0.0350.<\/li>\n
  • Randomized sample: 341; treatment duration: 12 weeks.<\/li>\n
  • Functional and ON-time measures support consistency, subject to the statistical hierarchy.<\/li>\n
  • No imbalance in treatment discontinuation was reported; individual adverse events require full review.<\/li>\n
  • Next evidence: replicate pivotal data, durability, full multiplicity plan and regulator feedback.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    ARISE is positive for its stated primary endpoint and meaningfully de-risks GPR6 pharmacology. It does not yet establish broad clinical superiority. The magnitude and durability of benefit, and the completeness of the safety dataset, should determine whether the mechanism changes Parkinson\u2019s practice.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: positive for the reported primary endpoint. Confidence in Facts: high for company-reported aggregate results and registry design. Confidence in Interpretation: moderate. Missing facts include complete confidence intervals, statistical hierarchy, regional consistency, responder distributions, dose-response details and long-term safety. Red-team: statistical success does not make a 0.61-hour mean difference automatically clinically transformative.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Cerevance reported that once-daily solengepras met the 12-week primary endpoint in Phase III ARISE, reducing daily OFF time versus placebo in levodopa-treated Parkinson\u2019s disease. The result validates the trial\u2019s non-dopaminergic GPR6 strategy at the…<\/p>\n","protected":false},"author":1,"featured_media":3657,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[978,975,977,979,107,976],"class_list":["post-3650","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-arise","tag-cerevance","tag-gpr6","tag-off-time","tag-parkinsons-disease","tag-solengepras"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3650"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3650\/revisions"}],"predecessor-version":[{"id":3664,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3650\/revisions\/3664"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3657"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}